Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.
Goldman JW, et al.
Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1.
Invest New Drugs. 2018.
PMID: 29196957
Free PMC article.
Clinical Trial.
Methods In part A (dose escalation), LY3007113 was administered orally every 12 h (Q12H) at doses ranging from 20 mg to 200 mg daily on a 28-day cycle until the maximum tolerated dose (MTD) was reached. ...Maximal inhibition (80%) of primary biomarker MAPK-activated protei …
Methods In part A (dose escalation), LY3007113 was administered orally every 12 h (Q12H) at doses ranging from 20 mg to 200 mg daily …